Joan Sellers

Nessuna posizione attualmente

Health Technology

Commercial Services

Consumer Services

Precedenti posizioni note di Joan Sellers

Società	Posizione	Inizio	Fine
Targeted Cell Therapies LLC	Corporate Officer/Principal	01/01/2010	01/01/2010
Vasculogic LLC	Fondatore	01/01/2006	01/01/2006
Vasculogic LLC	Presidente	-	01/01/2006
Transkaryotic Therapies, Inc. Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA.	Corporate Officer/Principal	01/01/1994	01/01/1994
NANOMIX CORPORATION	Direttore Tecnico/Scientifico/R&S	06/04/2011	-

State University of New York at Albany

Doctorate Degree

Distribuzione geografica

Stati Uniti

Posizioni

Corporate Officer/Principal	2
Chief Tech/Sci/R&D Officer	1
Founder	1

Settori

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Aziende private	4
Boston Therapeutics, Inc. Boston Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Lawrence, MA.	Health Technology
Targeted Cell Therapies LLC
Vasculogic LLC
Transkaryotic Therapies, Inc. Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA.	Commercial Services